Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

When even one tiny section of a person’s genetic code becomes mutated or modified, cells can begin to act out of ...

INmune Bio partners with UK-based Catapult to enhance cell therapy manufacturing for the production of its cell therapies.

A new collaboration facility, opened by Thermo Fisher Scientific, will work to make cell therapy developers’ research more accessible and optimized.

INmune Bio (INMB) has partnered with the Cell and Gene Therapy Catapult to establish large-scale, commercial-ready manufacturing for its cell ...

Following CORDStrom TM, INmune Bio plans to transition production of INKmune ®, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing and future trials in the US and ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ...

Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of sickle cell gene therapy ...

Scientists at the University of California, Riverside, have discovered how adult stem cells retain their regenerative power.